Diabetic Retinopathy Market Positioned for Accelerated Development Through 2034, DelveInsight Finds

DelveInsight's "Diabetic Retinopathy Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Diabetic Retinopathy, historical and forecasted epidemiology as well as the Diabetic Retinopathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Diabetic Retinopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Diabetic Retinopathy Market Forecast
https://www.delveinsight.com/sample-request/diabetic-retinopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Diabetic Retinopathy Market Report:
• The Diabetic Retinopathy market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In June 2025, Perfuse Therapeutics, Inc., a biopharmaceutical company focused on developing breakthrough therapies for ischemia-related eye diseases, announced positive outcomes from two Phase 2 clinical trials of PER-001. This innovative treatment targets two major causes of blindness worldwide: glaucoma and diabetic retinopathy. Both six-month, randomized, controlled studies evaluated PER-001, a first-in-class endothelin antagonist delivered via a slow-release, dissolvable implant injected into the eye's vitreous every six months. In both trials, PER-001 showed a significant improvement in vision compared to the control group.
• In May 2025, The FDA has granted approval to Roche's Susvimo (ranibizumab injection) at a 100 mg/mL dose for the treatment of diabetic retinopathy (DR). It is the first and only FDA-approved continuous delivery therapy proven to preserve vision in DR patients with a single refill required every nine months. This approval is supported by positive data from the Phase III Pavilion trial (NCT04503551).
• In May 2025, Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic retinopathy (DR), a serious eye condition that impacts nearly 10 million people in the US and over 100 million worldwide. Susvimo is the first and only continuous delivery therapy approved by the FDA that has demonstrated the ability to preserve vision in DR patients with only one refill every nine months. The treatment is now available in the US for retina specialists and patients with DR who have previously shown a positive response to at least two anti-vascular endothelial growth factor (VEGF) injections.
• In January 2025, The US-based biotechnology company Ocugen administered the first dose in a multicenter Phase I trial of OCU200 for treating diabetic macular edema (DMO).
• In September 2024, MSD (Merck & Co) and its subsidiary EyeBio have initiated the Phase IIb/III BRUNELLO clinical trial for Restoret (MK-3000, previously EYE103) aimed at treating diabetic macular oedema (DME). This randomized, double-masked trial will evaluate the efficacy and safety of two different doses of intravitreal (IVT) Restoret compared to the active control, ranibizumab, in DME patients.
• In March 2024, OcuTerra Therapeutics, Inc., a clinical-stage ophthalmology company focused on developing innovative treatments for eye diseases, has announced topline results from its Phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) trial for nesvategrast (OTT166), a selective RGD integrin inhibitor eye drop. The trial did not achieve its primary or key secondary efficacy endpoints. However, nesvategrast (OTT166 5%) demonstrated a favorable safety profile and was well tolerated, successfully meeting its primary safety endpoint. OcuTerra is now assessing strategic alternatives and will provide further updates in the future.
• Diabetic retinopathy (DR) is a significant neurovascular complication of diabetes, causing blindness in adults who are in their working years. The American Academy of Ophthalmology reports that with diabetes affecting an estimated 387 million people globally, a number expected to increase to 592 million by 2034, DR impacts approximately 93 million individuals worldwide.
• Diabetic retinopathy progresses through several stages: mild, where microaneurysms first appear; moderate, where blood vessels begin to lose their function; severe, involving blockages in blood vessels leading to the growth of new ones; and proliferative, the advanced stage characterized by the onset of new blood vessel formation.
• The primary choices for initial treatment are three anti-VEGF medications: EYLEA (aflibercept), LUCENTIS (ranibizumab), and AVASTIN (bevacizumab).
• Key Diabetic Retinopathy Companies: Palatin Technologies, Avirmax Biopharma, Ocular Therapeutix, Inc., MingSight Pharmaceuticals, Inc, OcuTerra Therapeutics, Inc., RemeGen Co., Ltd., Kodiak Sciences Inc, and others
• Key Diabetic Retinopathy Therapies: PL8177, ABI-110, OTX-TKI, MS-553, OTT166, RC28-E injection, KSI-301, and others
• The Diabetic Retinopathy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Diabetic Retinopathy pipeline products will significantly revolutionize the Diabetic Retinopathy market dynamics.

Diabetic Retinopathy Overview
Diabetic retinopathy is a complication of diabetes that affects the eyes. It occurs when high blood sugar levels damage the blood vessels in the retina, the light-sensitive tissue at the back of the eye. Over time, these damaged blood vessels may leak fluid or bleed, causing vision problems.

Get a Free sample for the Diabetic Retinopathy Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/diabetic-retinopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Diabetic Retinopathy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Diabetic Retinopathy Epidemiology Segmentation:
The Diabetic Retinopathy market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Diabetic Retinopathy
• Prevalent Cases of Diabetic Retinopathy by severity
• Gender-specific Prevalence of Diabetic Retinopathy
• Diagnosed Cases of Episodic and Chronic Diabetic Retinopathy

Download the report to understand which factors are driving Diabetic Retinopathy epidemiology trends @ Diabetic Retinopathy Epidemiology Forecast
https://www.delveinsight.com/sample-request/diabetic-retinopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Diabetic Retinopathy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Diabetic Retinopathy market or expected to get launched during the study period. The analysis covers Diabetic Retinopathy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Diabetic Retinopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Diabetic Retinopathy Therapies and Key Companies
• PL8177: Palatin Technologies
• ABI-110: Avirmax Biopharma
• OTX-TKI: Ocular Therapeutix, Inc.
• MS-553: MingSight Pharmaceuticals, Inc
• OTT166: OcuTerra Therapeutics, Inc.
• RC28-E injection: RemeGen Co., Ltd.
• KSI-301: Kodiak Sciences Inc

Discover more about therapies set to grab major Diabetic Retinopathy market share @ Diabetic Retinopathy Treatment Landscape
https://www.delveinsight.com/sample-request/diabetic-retinopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Diabetic Retinopathy Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Diabetic Retinopathy Companies: Palatin Technologies, Avirmax Biopharma, Ocular Therapeutix, Inc., MingSight Pharmaceuticals, Inc, OcuTerra Therapeutics, Inc., RemeGen Co., Ltd., Kodiak Sciences Inc, and others
• Key Diabetic Retinopathy Therapies: PL8177, ABI-110, OTX-TKI, MS-553, OTT166, RC28-E injection, KSI-301, and others
• Diabetic Retinopathy Therapeutic Assessment: Diabetic Retinopathy current marketed and Diabetic Retinopathy emerging therapies
• Diabetic Retinopathy Market Dynamics: Diabetic Retinopathy market drivers and Diabetic Retinopathy market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Diabetic Retinopathy Unmet Needs, KOL's views, Analyst's views, Diabetic Retinopathy Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.